These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 25301532)

  • 1. Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.
    Broadstock M; Ballard C; Corbett A
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):779-86. PubMed ID: 25301532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
    Kianirad Y; Simuni T
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Psychosis in Parkinson's disease].
    Rongve A; Auning E; Ehrt U; Arsland D
    Tidsskr Nor Laegeforen; 2012 Jan; 132(2):155-8. PubMed ID: 22278271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine as a treatment for psychosis in Parkinson's disease: a review.
    Musser WS; Akil M
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):1-9. PubMed ID: 8845691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease.
    Divac N; Stojanović R; Savić Vujović K; Medić B; Damjanović A; Prostran M
    Behav Neurol; 2016; 2016():4938154. PubMed ID: 27504054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of psychosis in Parkinson's disease.
    D'Souza C; Gupta A; Alldrick MD; Sastry BS
    Int J Clin Pract; 2003 May; 57(4):295-300. PubMed ID: 12800461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach.
    Friedman JH
    Expert Opin Pharmacother; 2024 Feb; 25(2):149-156. PubMed ID: 38344806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine for the treatment of psychosis in Parkinson's disease: chart review of 49 patients.
    Wagner ML; Defilippi JL; Menza MA; Sage JI
    J Neuropsychiatry Clin Neurosci; 1996; 8(3):276-80. PubMed ID: 8854298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of behavioural symptoms and dementia in Parkinson's disease.
    Hanagasi HA; Emre M
    Fundam Clin Pharmacol; 2005 Apr; 19(2):133-46. PubMed ID: 15810893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis.
    Sahli ZT; Tarazi FI
    Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
    Isaacson SH; Citrome L
    Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update expert opinion on management and research strategies in Parkinson's disease psychosis.
    Goldman JG; Vaughan CL; Goetz CG
    Expert Opin Pharmacother; 2011 Sep; 12(13):2009-24. PubMed ID: 21635198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.